Toxicological evaluation is important at every stage of HPAPI development and manufacturing—CDMOs help ensure new treatments are brought to market safely.
Over the last decade, the potential of fermentation-based manufacturing has expanded dramatically due to advances in synthetic biology and genetic engineering.